Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial
Phase of Trial: Phase III
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms BOOST
- 27 Mar 2017 Status changed from recruiting to discontinued.
- 25 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 29 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016, as reported by ClinicalTrials.gov.